Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.
暂无分享,去创建一个
M. Diccianni | A. Batova | R. Chang | L. Bridgeman | J. Yu | J. Pullen | A. Yu | W. Bowman | W P Bowman | A L Yu | J Yu | M Omura-Minamisawa | M B Diccianni | A Batova | R C Chang | L J Bridgeman | J Pullen | M. Omura‐Minamisawa
[1] D. Grandér,et al. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence , 1998, Oncogene.
[2] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[3] S. Ogawa,et al. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. , 1996, Blood.
[4] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[5] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[6] H. Koeffler,et al. Inhibition of growth of human leukemia cell lines by retrovirally expressed wild-type p16INK4A , 1997, Leukemia.
[7] M. Vidal,et al. The retinoblastoma protein binds to a family of E2F transcription factors , 1993, Molecular and cellular biology.
[8] M. Iravani,et al. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia , 1997, Oncogene.
[9] Gregory J. Hannon,et al. pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.
[10] A. Okamoto,et al. Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[11] F. Sigaux,et al. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. , 1996, Blood.
[12] G. Hannon,et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[13] T. Kumanishi,et al. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. , 1998, Cancer research.
[14] J. Bartek,et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.
[15] J. Shay,et al. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.
[16] G. Hannon,et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.
[17] P. Pollock,et al. CDKN2A/p16 is inactivated in most melanoma cell lines. , 1997, Cancer research.
[18] W Arap,et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.
[19] M. Link,et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.
[20] P. Meltzer,et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. , 1994, Cancer research.
[21] G. Peters,et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.
[22] C. Moskaluk,et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.
[23] F. Ajchenbaum‐Cymbalista,et al. Overexpression of cyclin D2 in chronic B-cell malignancies. , 1995, Blood.
[24] J. Bartek,et al. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.
[25] J. Decaprio,et al. Cyclin E, a redundant cyclin in breast cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[27] K. Kinzler,et al. Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.
[28] R. Hruban,et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.
[29] J. Bartek,et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.
[30] A. Look,et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. , 1993, Cancer research.
[31] M. Diccianni,et al. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. , 1996, Cancer letters.
[32] O. Olopade,et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.
[33] A. Okamoto,et al. IS-12 Mutation and altered expression of P16^ in human cancer. , 1995 .
[34] W. Hiddemann,et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.
[35] H. Kaneko,et al. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. , 1996, Leukemia.
[36] N. Dyson,et al. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. , 1990, The EMBO journal.
[37] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[38] Kevin Ryan,et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.
[39] N. Colburn,et al. Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. , 1993, Oncogene.
[40] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[41] M. Amylon,et al. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. , 1997, Leukemia research.
[42] J. Decaprio,et al. p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. , 1997, Blood.
[43] C. James,et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.
[44] B. Quesnel,et al. Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation , 1996, British journal of haematology.
[45] J. Herman,et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.
[46] F. Haluska,et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.
[47] H. Koeffler,et al. Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.
[48] R. Sclafani,et al. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[49] D. Carson,et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.
[50] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[51] Steven K. Hanks,et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.
[52] Y. Hayashi,et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. , 1995, Blood.
[53] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[54] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[55] K. Keyomarsi,et al. Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[56] S. Smith,et al. Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells. , 1996, Leukemia.
[57] F. Kaye,et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[58] J. Lapointe,et al. A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.
[59] E. Harlow,et al. Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.
[60] J. Herman,et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.
[61] M. Omura-Minamisawa,et al. Frequent deregulation of p16 and the p16/G1 cell cycle‐regulatory pathway in neuroblastoma , 1999, International journal of cancer.
[62] M. Loda,et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.
[63] E. Livingston,et al. Deletion of P15 (MTS2) in head and neck squamous cell carcinomas. , 1998, The Journal of surgical research.
[64] S. Tavtigian,et al. Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.
[65] C. D. Edwards,et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.